Volume 16, Issue 1 (Winter 2025)                   Caspian J Intern Med 2025, 16(1): 66-72 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Homayounfar S, Ayatollahi H, Ferns G, Hemmatan Attarbashi R, Gharib M, Sheikhi M, et al . The prevalence of Fibroblast Growth Factor Receptor 1 Gene (FGFR1) amplification in Non-Small Cell Lung Cancer (NSCLC) by Real-time PCR. Caspian J Intern Med 2025; 16 (1) :66-72
URL: http://caspjim.com/article-1-3792-en.html
Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , jafarianah@mums.ac.ir
Abstract:   (156 Views)
Background: Comprehensive molecular assessment of cancers could open up new horizons for novel therapies. Fibroblast growth factor receptor 1 (FGFR1) gene amplification has been previously demonstrated in non-small cell lung cancer (NSCLC) patients. The current study aimed to evaluate the prevalence of FGFR1 gene amplification and its association with clinical and demographic data in a group of NSCLC patients.
Methods: The present study was performed on eighty-eight NSCLC patients who underwent bronchoscopy or surgery in Qaem Hospital, Mashhad, between 2010 and 2016. FGFR1 gene amplification was detected using real-time PCR assay on DNA extracted from paraffin-embedded tissue blocks of patients. Also, patients' clinical and demographic data, such as their survival, were evaluated. Statistical analysis was carried out using SPSS software.
Results: Seventeen (19.31%) out of eighty-eight patients with NSCLC presented FGFR1 gene amplification. Besides, we found a significant association between FGFR1 amplification and cigarette smoking (p-value= 0.01; OR: 4.08). Although cases with squamous cell carcinoma (SCC) showed a higher prevalence of FGFR1 amplification compared to adenocarcinoma patients, the difference was not statistically significant (p-value> 0.05). In addition, our findings showed no relationship between FGFR1 gene amplification and other clinical and demographic factors, including age, sex, grade, tumor operability, and survival.
Conclusion: The frequency of FGFR1 amplification is estimated at 20% in the current study (26% in SCC versus 11% in adenocarcinoma; p-value= 0.07). Moreover, we found a direct association between FGFR1 amplification and cigarette smoking. However, no significant relationship with survival or other factors was observed.

 
Full-Text [PDF 601 kb]   (61 Downloads)    
Type of Study: Original Article | Subject: Oncology
Received: 2022/12/14 | Accepted: 2024/01/30 | Published: 2025/10/4

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Caspian Journal of Internal Medicine

Designed & Developed by: Yektaweb